Pune, India, 2022 /MRFR Press Release/- Market Research Future has a half-cooked research report on the global nephroblastoma treatment market.
The Nephroblastoma Treatment Market is anticipated to reach USD 1,683.0 Million by 2030 at a 4.8 % CAGR during the forecast period 2022-2030.
Nephroblastoma is the most common type of kidney cancer in children. The prevalence rate of nephroblastoma is about 9 out of 10 kidney cancers in children. Tumors which affects only one kidney and have only one tumor are unilateral. Around 5-10% of children with nephroblastoma have more than one tumor in the same kidney. About 5% of children with nephroblastoma have tumors in both kidneys which means they have bilateral disease. Nephroblastoma often become large and occasionally some newly found nephroblastoma are larger than the kidney itself. Currently scenario indicates the survival rate of children suffering from nephroblastoma is approximately 80% to 90%.
Global nephroblastoma treatment consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas hold the largest share of the global nephroblastoma treatment market owing to the growing incidence of kidney cancers in the U.S. The Europe is the second largest market for the nephroblastoma treatment market owing to the high prevalence rate of this disease in the Eastern European regions. The Asia Pacific is expected to be the fastest growing region during the forecasted period. The incidence ratio of nephroblastoma is 1 in every 10,000 with 85% of patients usually younger than 6 years. The screening is usually performed on infants with age of 2-3 year. Girls are affected more than boys with different incidence for children of different ethnicities. For instance, the incidence rate in Asia is substantially lower than in European or American children.
Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Nephroblastoma Treatment Market Research Report
The nephroblastoma treatment is segmented on the basis of types, drugs, diagnosis, treatment, distribution channel, and end-users. On the basis of the types, the market is segmented into favorable histology, unfavorable histology (anaplastic wilms tumor). On the basis of the drugs, the market is segmented into dactinomycin (cosmegen), doxorubicin (adriamycin), vincristine (vincasar pfs, oncovin), cyclophosphamide (cytoxan, neosar), etoposide (toposar, vepesid), irinotecan (camptosar), and others. On the basis of the diagnosis, the market is segmented into ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), chest x-ray, bone scan, lab tests and others. On the basis of the treatment, the market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery is classified into radical nephrectomy, partial nephrectomy (nephron-sparing surgery), and others. On the basis of the distribution channel, the market is segmented into hospital pharmacies, e-commerce, drug stores, retail pharmacy, and others. On the basis of the end-user, the market is segmented into hospitals, cancer centers, surgical centers and ambulatory surgical center.
Some of key the players in the global nephroblastoma treatment market are Bayer HealthCare LLC (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sanofi Pasteur Inc. (U.S.), Merck & Co. Inc. (U.S.), MediLexicon International Ltd (U.S.), Bristol-Myers Squibb Company (U.S.), Apotex Inc. (U.S.), and others.
Leading companies partner with us for data-driven Insights.